MedTrace Logo

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

NCT01852708 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1059

Last updated 2020-12-30

No results posted yet for this study

Summary

The purpose of this study is to collect maternal blood samples from pregnant women carrying a fetus with a confirmed diagnosis of chromosomal abnormality or genetic disorder including microdeletions in order to further develop a non-invasive prenatal screening test based on fetal DNA isolated from maternal blood.

Conditions

  • Trisomy 21
  • Trisomy 18
  • Trisomy 13
  • Sex Chromosome Abnormalities
  • Microdeletion Syndromes

Sponsors & Collaborators

  • Natera, Inc.

    lead INDUSTRY

Principal Investigators

  • Zachary Demko, PhD · Natera, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • United States
  • Spain
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01852708 on ClinicalTrials.gov